Volume 13

Issue 2

Article 10

2005

A fast GC-MS screening procedure for ketamine and its
metabolites in urine samples

Follow this and additional works at: https://www.jfda-online.com/journal

Recommended Citation
Lin, H.-R. and Lua, A.-C. (2005) "A fast GC-MS screening procedure for ketamine and its metabolites in
urine samples," Journal of Food and Drug Analysis: Vol. 13 : Iss. 2 , Article 10.
Available at: https://doi.org/10.38212/2224-6614.2538

This Original Article is brought to you for free and open access by Journal of Food and Drug Analysis. It has been
accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and Drug
Analysis.

107
藥物食品分析

Journal of Food and Drug Analysis, Vol. 13, No. 2, 2005, Pages 107-111

第十三卷

第二期

A Fast GC-MS Screening Procedure for Ketamine and Its
Metabolites in Urine Samples
HUEI-RU LIN1 AND AHAI-CHANG LUA2*
1.
2.

Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan, R.O.C.

Department of Laboratory Medicine and Biotechnology, Tzu Chi University, 701, Sec. 3, Chung Yan Rd., Hualien City 970, Taiwan, R.O.C.
(Received: October 28, 2004; Accepted: January 21, 2005)

ABSTRACT
The rapid increase of ketamine abuse worldwide has created a need for a fast and efficient screening procedure. Currently, there is
no commercially available immunoassay. We developed a simple extraction and GC/MS screening procedure to screen out negative
samples. Urine samples (1 mL) were spiked with ketamine-d4 as internal standard. After liquid-liquid extraction, samples were
screened for ketamine (K) and its two metabolites, norketamine (NK) and dehydronorketamine (DHNK), with GC/MS without derivatization. The total analytical time is 5 min for each sample. The detection limit for K, NK and DHNK was 10 ng/mL, 10 ng/mL and 30
ng/mL, respectively. The within-run precision and accuracy for 80, 160, 400 ng/mL of K, NK and DHNK were all between -12.50%
and 8.17%. We collected 163 urine samples from disco-dancing clubs in Taiwan. Samples were screened and confirmed with GC/MS.
The total analytical time for GC-MS confirmation is 20 min per sample. The sensitivity is 98.9% and specificity is 100%. This
screening method is rapid, sensitive and applicable to forensic and clinical toxicological analyses.
Key words: fast screen, ketamine, GC-MS

INTRODUCTION
Ketamine, (R, S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone, a derivative of phencyclidine hydrolchloride (PCP), was introduced in the 1960s as a dissociative
anesthetic(1). Like PCP, ketamine interacts with the Nmethyl-D-aspartate (NMDA) channel(2). It is the psychedelic effects that ketamine shares with PCP, including
dream-like hallucinations, floating sensations, perceptions
of creativity and feeling of arousal(3). Ketamine is also
commonly employed as a veterinary anesthetic.
In addition to its legitimate uses, ketamine is also a
drug of abuse commonly identified by street names such as
Special K, Vitamin K and K. Along with other drugs such
as methylenedioxymethamphetamine (MDMA, Ecstasy)
and gamma-hydroxybutyrate (GHB), ketamine has become
increasingly popular with the promotion and growth of the
rave culture(4,5). The abuser frequently uses large street
doses in an attempt to yield “near-death” experiences(6).
And there were reports of increased abuse of ketamine and
ketamine-related deaths(7-9).
Ketamine undergoes an extensive liver metabolism by
CYP-450 demethylation to norketamine (NK), followed by
dehydrogenation to dehydronorketamine (DHNK) (10) .
Some reports suggested that DHNK was an analytical
artifact of high-temperature(11,12). Moore et al.(7) used
liquid chromatography-mass spectrometry (LC-MS) at low
temperature to provide evidence that DHNK is a real
metabolite of K. In our previous paper(13), we also used
non-derivatized method to analyze K, NK and DHNK to
* Author for correspondence. Tel: +886-38-561635;
Fax: +886-38-571917; E-mail: ahai@mail.tcu.edu.tw

also confirm this point. According to the data of Moore et
al., DHNK would be the most sensitive target analyte for
potential immunoassay. But to date, there is no commercial
immunoassay available.
Here, we developed a simple method to simultaneously
screen K, NK and DHNK in urine samples.

MATERIALS AND METHODS
I. Chemicals
Ketamine, NK, ketamine-d4 (K-d4), and norketamined4 (NK-d4) were purchased from Cerilliant (Austin TX,
USA). DHNK was purchased from Formosa Laboratories
(Taiwan). Methanol and ethyl acetate (EA) were purchased
from Mallinckrodt, USA. Dichloromethane and isobutanol
were purchased from J. T. Baker, USA. Sodium hydroxide,
potassium hydroxide, and concentrated hydrochloric acid
were purchased from Riedel-deHaën, Germany. All the
organic solvents and chemicals are reagent grade.
II. Urine Samples
Urine samples were collected from participants
suspected of abusing ketamine in a disco-dancing club in
Taipei City, Taiwan.
III. Instrument
A Hewlett Packard GC (6890) coupled to a mass
detector (5973) equipped with an autosampler and a HP-
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5MS capillary column (12.5 m × 0.20 mm i.d., 0.33 µm
film thickness) (Agilent Technologies, Palo Alto, CA) was
used for GC-MS analysis.

138, 118. Underlined mass fragments were employed for
quantification. Cutoff value was set as 100 ng/mL for K,
NK, or DHNK. Total analysis time was 20 min per sample.
A solvent blank was run in between samples.

IV. GC-MS Screening Procedure
To a clean borosilicate glass tube (Kimble 10 × 75
mm), 1 mL of urine sample was added and spiked with
internal standard K- d4 (100 ng in 20 µL of methanol). The
mixture was alkalinized with 1 mL of 1N sodium hydroxide
and extracted with 0.2 mL of hexane by vortex, then stood
for 2 min. Eighty microliter of hexane layer was collected
for GC-MS analysis.
Two microliter was injected (splitless). Injection port
and interface temperature were maintained at 260˚C and
280˚C, respectively. GC oven was held at 160˚C for 0.08
min then increased to 220˚C at 35˚C/min and held for 0.01
min, then ramped to 260˚C at 40˚C/min, then held at the
temperature for 0.01 min. Flow rate was 1 mL/min.
Selected ion monitoring mode was used for the analysis.
The extracted ion ratios of m/z 209/184 (K/K-d 4), m/z
166/184 (NK/K- d4) and m/z 153/184 (DHNK/K- d4) were
used for quantification. Cutoff value was set as 100 ng/mL
for K, NK or DHNK. Total analysis time was 5 min per
sample. There was no solvent blank in between samples.
V. GC-MS Confirmation Procedure
Detailed procedure was described in our previous publication(13). Briefly, urine samples were spiked with 200 ng
of K-d4 and NK- d4 as internal standards. Samples were
extracted with 4 mL of dichloromethane containing 10%
isobutanol. The organic layer was evaporated to dryness
and reconstituted in 100 µL of EA, and 1-3 µL was injected
in splitless mode. Selected ion monitoring mode was used
for GC/MS analysis. Ions monitored were as follows: K,
m/z 209, 180, 182; NK, m/z 166, 168, 195; K-d4, m/z 184,
186, 213; NK-d4, m/z 170, 172, 199 and DHNK, m/z 153,

RESULTS
I. Performance Characteristics of the GC/MS Screening
Procedure
(I) GC-MS chromatogram
Total ion chromatogram and the extract ion chromatogram of K-d 4 , K, NK, and DHNK with GC-MS
screening method were shown in Figures 1 and 2, respectively. The total analytical time is 5.0 min, including the
time required for sample injection and for oven to return to
initial temperature.
(II) Precision and accuracy
The within-run precision (% CV) of the three different
control levels (80, 160, 400 ng/mL) of K, NK and DHNK
were all less than 8.17%. The error of accuracy was all
between –12.5% and 5.75% for the controls. These data
were shown in Table 1. Accuracy of the procedure was
presented as percent error, calculated as follows:
[(measured value - expected value)/ expected value] ×
100%.
(III) Linearity and detection limit
The linearity of the method was determined with calibration standards at 0, 100, 200, and 500 ng/mL. Linear
regression of the calibration curve for K was y = 0.0036x +
0.0046, R2 = 0.9990, for NK was y = 0.009x + 0.00961, R2
= 0.9982, and for DHNK was y = 0.0054x + 0.0233, R2 =

30000

Abundance

25000
20000
15000
10000
5000

1.10

1.20

1.30

1.40

1.50

1.60

1.70

1.80

1.90

2.00

2.10

2.20

2.30

2.40

2.50

2.60

2.70

Retention time (min)

Figure 1. Total ion chromatogram of cutoff calibrator with GC-MS screening method (cutoff concentration of K, NK and DHNK is 100 ng/mL).
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Figure 2. The extract ion chromatogram of cutoff calibrator (K-d4: m/z 184, K: m/z 209, NK: m/z 166, and DHNK: m/z 153).

Table 1. Within-run precision and accuracy of ketamine, norketamine and dehydronorktamine determined with GC-MS screening procedurea
Concentration
80 ng/mL
160 ng/mL
400 ng/mL
Ketamine
Precision (CV, %)
3.59
1.78
2.34
Accuracy (error, %)
3.75
2.50
5.75
Norketamine
Precision (CV, %)
2.46
1.20
2.46
Accuracy (error, %)
-5.00
-3.12
-0.75
Dehydronorketamine
Precision (CV, %)
8.17
1.41
2.84
Accuracy (error, %)
-12.50
-11.25
-7.50
a
Ions monitored: K, m/z 209/184; NK, m/z 166/184; DHNK, m/z 153/184.

Table 2. Within-run and between-day precision and accuracy of dehydronorktamine determined with GC-MS confirmation procedurea
Concentration
80 ng/mL
160 ng/mL
400 ng/mL
Within-run
Precision (CV, %)
7.90
4.56
9.31
Accuracy (error, %)
-3.75
-6.67
-9.25
Between-day
Precision (CV, %)
2.13
1.58
2.34
Accuracy (error, %)
-1.56
-1.13
-1.13
a
Ions monitored: DHNK, m/z 153/170.

0.9987. The limit of detection, LOD, (defined as the lowest
concentration at which all replicates produce results with
signal to noise ratio greater than 3) is 10 ng/mL for K, 10
ng/mL for NK, and 30 ng/mL for DHNK.

II. Performance Characteristics of the GC/MS Confirmation Procedure
(I) Precision and accuracy
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Detailed results were reported in our previous publication
except for DHNK. Calibration curves were
generated with different concentration of K, NK and
DHNK (0, 100, 200, and 500 ng/mL). Linear regression of
the calibration curve for DHNK was y = 0.0019x – 0.0108,
R2 = 0.9984. The within-run and between-day precision
(%CV) and accuracy (error, %) of three different levels of
DHNK at 80, 160, 400 ng/mL are between –9.25% and
9.31%. These data were shown in Table 2.

Table 3. Correlation of the GC-MS screening and GC-MS confirmation methoda
GC-MS screening
GC-MS confirmation
+
–
+
88
1
–
0
74
a
Cutoff concentration for GC-MS screening and GC-MS confirmation
is 100 ng/mL of K, NK or DHNK. Sensitivity: 98.9%, specificity:
100%.

(II) Linearity and detection limit

33 cases. In this study, the concentration of DHNK was
greater than K or NK in 76 of 88 positive cases. There
were 18 samples that DHNK is the only analyte with concentration higher than cutoff value (100 ng/mL). These
data are in agreement with those reported previously and
suggested that DHNK would be the target analyte of choice
for screening.
Traditionally, GC equipped with NPD(16), FID(17) and
(18)
MS
were employed to analyze samples with prior
extraction, concentration, and derivatization of analytes
from biological samples. It may take one to two hours in
some method (16,18). The long analytical time rendered
those methods not suitable for screening purpose.
In this study, we presented a simple screening
procedure for K, NK, and DHNK. There was just one
liquid-liquid extraction step without further evaporation to
dryness. The whole extraction procedure took less than 10
min and used less organic solvent (200 µL of hexane). An
experienced technician can process 60 samples in one hour.
The total analytical time is 5 min, including temperature
equilibrium. No solvent blank was run in between samples
to speed up the process. It’s because any false positive
results will be corrected by subsequent confirmation
procedure. The analysis time of GC/MS confirmation
method is 20 min/sample. A blank was usually added
between samples during analysis to prevent carryover. The
analysis time of confirmation method is thus 40
min/sample. Compared with the analysis time of screening
method (5 min/sample), the screening procedure required
only 1/8 of the instrument analysis time. Cutoff concentration for GC-MS screening and GC-MS confirmation was
set at 100 ng/mL of K, NK and DHNK. Good correlation
between GC-MS screening and confirmation was obtained
(sensitivity is 98.9% and specificity is 100%).
Although the LOD of our method was less than 10
ng/mL, the cutoff was set at 100 ng/mL, substantially
higher than the LOD. This is in accordance with the
guideline established by the Department of Health,
Taiwan (14) . For example, the LOD for morphine and
codeine was 30 ng/mL and 10 ng/mL, respectively, in one
study (19) . The cutoff concentration for morphine and
codeine in GC/MS confirmation assay was set at 300
ng/mL(14).
It is a common practice to employ methods with
different analytical principles for screening and confirmation purposes. However, when there were discrepancies
between the screening and confirmation results, GC/MS

(13)

LOD was 1 ng/mL for K, 5 ng/mL for NK(13) and 20
ng/mL for DHNK. LOQ (defined as the lowest concentration detected that passed the qualifying ion ratio requirement and the concentration determined was within 20% of
expected value) was 5 ng/mL for K, 10 ng/mL for NK(13)
and 40 ng/mL for DHNK. Range of linearity was 7
µg/mL, 4 µg/mL, and 5 µg/mL for K, NK(13), and DHNK,
respectively.
III. Sensitivity and Specificity
In order to determine the sensitivity and specificity of
GC-MS screening procedure, a group of 163 urine samples
collected from disco-dancing club participants were
screened with the GC-MS screening method. Every sample
was also confirmed with GC-MS. Results are shown in
Table 3. There were 88 positive, 74 negative samples and
one false negative sample. The screening results of this one
false negative sample is 98, 20, 19 ng/mL for K, NK and
DHNK, respectively. And the confirmation results of this
sample is 103, 37, 79 ng/mL for K, NK and DHNK, respectively. Sensitivity (defined as the number of true positive
samples divided by the sum of true positive plus false
negative samples) of the GC-MS screening procedure is
98.9% and specificity (defined as the number of true
negative samples divided by the sum of true negative plus
false positive samples) is 100%.

DISCUSSION
The rapid increase of ketamine abuse has created a
need for a fast and cost effective procedure to screen out
negative samples before confirmation with GC/MS.
Immunoassays with high specificity and sensitivity are the
methods of choice to screen drugs of abuse in urine
samples(14). However, there was no commercially available
immunoassay for ketamine or its metabolites.
Ketamine is believed to be metabolized to at least two
major metabolites: NK and DHNK. Although DHNK was
argued to be an artifact(12,15), many reports(7,13) including
our data provided evidence to support DHNK as a true
metabolite of ketamine. Moore et al.(7) employing LC-MS
to analyze samples reported that the concentration of
DHNK was greater than K and NK concentration in 28 of
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confirmation results was the one accepted (gold standard).
Theoretically only the GC/MS confirmation was required to
obtain results. The main purpose of a screening procedure
was to screen out negative samples before confirmation in
order to save time and money. Our screening procedure
satisfied the two purposes of a screening program: saving
time (requires only 1/8 of the time) and money (in terms of
instrument time). Presumptive positive samples were
confirmed with GC/MS procedure. As other screening
procedure, ours was capable of screening out negative
samples before confirmation. We have analyzed 163
samples and observed no false positive result.
The GC-MS screening method we described is rapid,
sensitive and specific. It can be employed to screen K, NK
and DHNK in urine samples.

CONCLUSIONS
The screening procedure is the first reported procedure
to simultaneously analyze K, NK and DHNK. The GC-MS
screening method is rapid, sensitive and suitable for high
volume screening for ketamine abuse.
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